Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 498

1.

A urinary extracellular vesicle microRNA biomarker discovery pipeline; from automated extracellular vesicle enrichment by acoustic trapping to microRNA sequencing.

Ku A, Ravi N, Yang M, Evander M, Laurell T, Lilja H, Ceder Y.

PLoS One. 2019 May 29;14(5):e0217507. doi: 10.1371/journal.pone.0217507. eCollection 2019.

2.

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Wu X, Scott H, Carlsson SV, Sjoberg DD, Cerundolo L, Lilja H, Prevo R, Rieunier G, Macaulay V, Higgins GS, Verrill CL, Lamb AD, Cunliffe VT, Bountra C, Hamdy FC, Bryant RJ.

Prostate. 2019 Jul;79(10):1079-1089. doi: 10.1002/pros.23817. Epub 2019 May 18.

3.

The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.

Smith Byrne K, Appleby PN, Key TJ, Holmes MV, Fensom GK, Agudo A, Ardanaz E, Boeing H, Bueno-de-Mesquita HB, Chirlaque MD, Kaaks R, Larrañaga N, Palli D, Perez-Cornago A, Quirós JR, Ricceri F, Sánchez MJ, Tagliabue G, Tsilidis KK, Tumino R, Fortner RT, Ferrari P; PRACTICAL Consortium, Riboli E, Lilja H, Travis RC.

Ann Oncol. 2019 Apr 8. pii: mdz121. doi: 10.1093/annonc/mdz121. [Epub ahead of print]

PMID:
31089709
4.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
5.

Clinical Chemistry's Special Issue on Men's Health.

Park JY, Deutsch MB, Koenig W, Lilja H, Platz EA.

Clin Chem. 2019 Jan;65(1):1-3. doi: 10.1373/clinchem.2018.299172. No abstract available.

PMID:
30602467
6.

Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function.

Srinivasan S, Stephens C, Wilson E, Panchadsaram J, DeVoss K, Koistinen H, Stenman UH, Brook MN, Buckle AM, Klein RJ, Lilja H, Clements J, Batra J; Practical Consortium.

Clin Chem. 2019 Jan;65(1):e1-e9. doi: 10.1373/clinchem.2018.295790. Epub 2018 Dec 11.

PMID:
30538125
7.

Perspective on Prostate Cancer Screening.

Carlsson SV, Lilja H.

Clin Chem. 2019 Jan;65(1):24-27. doi: 10.1373/clinchem.2018.293514. Epub 2018 Nov 20. No abstract available.

PMID:
30459166
8.

Diminished DEFA6 Expression in Paneth Cells Is Associated with Necrotizing Enterocolitis.

Markasz L, Wanders A, Szekely L, Lilja HE.

Gastroenterol Res Pract. 2018 Oct 21;2018:7345426. doi: 10.1155/2018/7345426. eCollection 2018.

9.

Functional outcome and health-related quality of life in patients with sacrococcygeal teratoma - a Swedish multicenter study.

Hambraeus M, Al-Mashhadi A, Wester T, Svensson PJ, Stenström P, Lilja HE.

J Pediatr Surg. 2018 Oct 22. pii: S0022-3468(18)30667-5. doi: 10.1016/j.jpedsurg.2018.10.044. [Epub ahead of print]

PMID:
30420172
11.

Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, Häggström C, Hallmans G, Rönn AC, Stattin P, Melander O, Ulmert D, Lilja H, Klein RJ.

Eur Urol. 2018 Dec;74(6):710-719. doi: 10.1016/j.eururo.2018.06.021. Epub 2018 Jul 7.

PMID:
30289108
12.

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.

Thorek DLJ, Ku AT, Mitsiades N, Veach D, Watson PA, Metha D, Strand SE, Sharma SK, Lewis JS, Abou DS, Lilja HG, Larson SM, McDevitt MR, Ulmert D.

Clin Cancer Res. 2019 Jan 15;25(2):881-891. doi: 10.1158/1078-0432.CCR-18-1521. Epub 2018 Sep 25.

13.

Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.

Frånlund M, Arnsrud Godtman R, Carlsson SV, Lilja H, Månsson M, Stranne J, Hugosson J.

Scand J Urol. 2018 Aug;52(4):256-262. doi: 10.1080/21681805.2018.1508166. Epub 2018 Sep 21.

PMID:
30241447
14.

Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.

Preston MA, Gerke T, Carlsson SV, Signorello L, Sjoberg DD, Markt SC, Kibel AS, Trinh QD, Steinwandel M, Blot W, Vickers AJ, Lilja H, Mucci LA, Wilson KM.

Eur Urol. 2019 Mar;75(3):399-407. doi: 10.1016/j.eururo.2018.08.032. Epub 2018 Sep 17.

PMID:
30237027
15.

Surgical repair of long-gap esophageal atresia: A retrospective study comparing the management of long-gap esophageal atresia in the Nordic countries.

Stadil T, Koivusalo A, Pakarinen M, Mikkelsen A, Emblem R, Svensson JF, Ehrén H, Jönsson L, Bäckstrand J, Lilja HE, Donoso F, Thorup JM, Sæter T, Rasmussen L, Pedersen RN, Stenström P, Arnbjörnsson E, Óskarsson K, Qvist N.

J Pediatr Surg. 2019 Mar;54(3):423-428. doi: 10.1016/j.jpedsurg.2018.07.023. Epub 2018 Sep 1.

PMID:
30220451
16.

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.

Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, Bova GS, Visakorpi T.

Br J Cancer. 2018 Aug;119(3):347-356. doi: 10.1038/s41416-018-0172-0. Epub 2018 Jul 10.

PMID:
29988112
17.

Acoustic Enrichment of Extracellular Vesicles from Biological Fluids.

Ku A, Lim HC, Evander M, Lilja H, Laurell T, Scheding S, Ceder Y.

Anal Chem. 2018 Jul 3;90(13):8011-8019. doi: 10.1021/acs.analchem.8b00914. Epub 2018 Jun 11.

PMID:
29806448
18.

Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46.

Vickers A, Nordström T, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2018 Aug;74(2):e35-e36. doi: 10.1016/j.eururo.2018.04.027. Epub 2018 May 3. No abstract available.

PMID:
29731258
19.

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.

McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, Larson SM, Ulmert D.

Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w.

20.

Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Sjoberg DD, Vickers AJ, Assel M, Dahlin A, Poon BY, Ulmert D, Lilja H.

Eur Urol. 2018 Jun;73(6):941-948. doi: 10.1016/j.eururo.2018.02.016. Epub 2018 Mar 5.

21.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

22.

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project.

Assel MJ, Gerdtsson A, Thorek DLJ, Carlsson SV, Malm J, Scardino PT, Vickers A, Lilja H, Ulmert D.

Oncotarget. 2017 Dec 5;9(5):5778-5785. doi: 10.18632/oncotarget.22981. eCollection 2018 Jan 19.

23.

Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.

Kim K, Watson PA, Lebdai S, Jebiwott S, Somma AJ, La Rosa S, Mehta D, Murray KS, Lilja H, Ulmert D, Monette S, Scherz A, Coleman JA.

Clin Cancer Res. 2018 May 15;24(10):2408-2416. doi: 10.1158/1078-0432.CCR-17-3474. Epub 2018 Feb 20.

24.

Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.

Vickers A, Vertosick EA, Sjoberg DD, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2018 Jun;199(6):1470-1474. doi: 10.1016/j.juro.2018.01.070. Epub 2018 Jan 31.

PMID:
29366640
25.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

26.

Reducing WBC background in cancer cell separation products by negative acoustic contrast particle immuno-acoustophoresis.

Cushing K, Undvall E, Ceder Y, Lilja H, Laurell T.

Anal Chim Acta. 2018 Feb 13;1000:256-264. doi: 10.1016/j.aca.2017.11.064. Epub 2017 Dec 5.

PMID:
29289318
27.

Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.

Hugosson J, Godtman RA, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Scand J Urol. 2018 Feb;52(1):27-37. doi: 10.1080/21681805.2017.1411392. Epub 2017 Dec 18.

28.

A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H.

Eur Urol Focus. 2017 Nov 11. pii: S2405-4569(17)30258-4. doi: 10.1016/j.euf.2017.11.002. [Epub ahead of print]

29.

Clinical-Scale Cell-Surface-Marker Independent Acoustic Microfluidic Enrichment of Tumor Cells from Blood.

Magnusson C, Augustsson P, Lenshof A, Ceder Y, Laurell T, Lilja H.

Anal Chem. 2017 Nov 21;89(22):11954-11961. doi: 10.1021/acs.analchem.7b01458. Epub 2017 Nov 9.

30.

Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.

Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H, Vickers AJ.

Eur Urol. 2018 Jun;73(6):961-967. doi: 10.1016/j.eururo.2017.10.004. Epub 2017 Oct 21.

31.

Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).

Smith K, Byrne, Castaño JM, Chirlaque MD, Lilja H, Agudo A, Ardanaz E, Rodríguez-Barranco M, Boeing H, Kaaks R, Khaw KT, Larrañaga N, Navarro C, Olsen A, Overvad K, Perez-Cornago A, Rohrmann S, Sánchez MJ, Tjønneland A, Tsilidis KK, Johansson M, Riboli E, Key TJ, Travis RC.

J Clin Oncol. 2017 Apr 20;35(12):1297-1303. doi: 10.1200/JCO.2016.70.0062. Epub 2017 Mar 6.

32.

Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis.

Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, Mai V, Gregory KE, Kroll JS, McMurtry V, Ferris MJ, Engstrand L, Lilja HE, Hollister EB, Versalovic J, Neu J.

Microbiome. 2017 Mar 9;5(1):31. doi: 10.1186/s40168-017-0248-8. Review.

33.

Sutures impregnated with carbazate-activated polyvinyl alcohol reduce intraperitoneal adhesions.

Fredriksson F, Sellberg F, Bowden T, Engstrand T, Berglund D, Lilja HE.

J Pediatr Surg. 2017 Nov;52(11):1853-1858. doi: 10.1016/j.jpedsurg.2017.01.058. Epub 2017 Feb 1.

PMID:
28196659
34.

Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.

Hoffmann TJ, Passarelli MN, Graff RE, Emami NC, Sakoda LC, Jorgenson E, Habel LA, Shan J, Ranatunga DK, Quesenberry CP, Chao CR, Ghai NR, Aaronson D, Presti J, Nordström T, Wang Z, Berndt SI, Chanock SJ, Mosley JD, Klein RJ, Middha M, Lilja H, Melander O, Kvale MN, Kwok PY, Schaefer C, Risch N, Van Den Eeden SK, Witte JS.

Nat Commun. 2017 Jan 31;8:14248. doi: 10.1038/ncomms14248.

35.

Risk factors for postoperative mortality in congenital diaphragmatic hernia: a single-centre observational study.

Kadir D, Lilja HE.

Pediatr Surg Int. 2017 Mar;33(3):317-323. doi: 10.1007/s00383-016-4032-9. Epub 2016 Dec 16.

36.

Patient-reported Swedish nationwide outcomes of children and adolescents with total colonic aganglionosis.

Stenström P, Brautigam M, Borg H, Graneli C, Lilja HE, Wester T.

J Pediatr Surg. 2017 Aug;52(8):1302-1307. doi: 10.1016/j.jpedsurg.2016.11.033. Epub 2016 Nov 17.

PMID:
27912975
37.

Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D.

Sci Transl Med. 2016 Nov 30;8(367):367ra167.

38.

Absent ileocecal valve predicts the need for repeated step in children.

Wester T, Lilja HE, Stenström P, Pakarinen M.

Surgery. 2017 Mar;161(3):818-822. doi: 10.1016/j.surg.2016.09.011. Epub 2016 Nov 3.

PMID:
27816208
39.

Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.

Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H.

J Urol. 2017 Apr;197(4):1041-1047. doi: 10.1016/j.juro.2016.10.089. Epub 2016 Nov 1.

40.

Risk Factors for Anastomotic Strictures after Esophageal Atresia Repair: Prophylactic Proton Pump Inhibitors Do Not Reduce the Incidence of Strictures.

Donoso F, Lilja HE.

Eur J Pediatr Surg. 2017 Feb;27(1):50-55. doi: 10.1055/s-0036-1593607. Epub 2016 Oct 21.

PMID:
27769086
41.

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA.

Cancer. 2016 Nov 15;122(21):3386-3393. doi: 10.1002/cncr.30192. Epub 2016 Jul 26.

42.

Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.

Vickers A, Vertosick EA, Sjoberg DD, Roobol MJ, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2017 Mar;197(3 Pt 1):607-613. doi: 10.1016/j.juro.2016.09.086. Epub 2016 Sep 28.

43.

Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer.

Neal D, Lilja H.

Eur Urol. 2016 Dec;70(6):993-994. doi: 10.1016/j.eururo.2016.06.014. Epub 2016 Jun 23. No abstract available.

PMID:
27344293
44.

Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 Sep;95:224. doi: 10.1016/j.urology.2016.05.046. Epub 2016 Jun 1. No abstract available.

PMID:
27262394
45.

Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.

Loeb S, Lilja H, Vickers A.

Curr Opin Urol. 2016 Sep;26(5):459-65. doi: 10.1097/MOU.0000000000000316. Review.

46.

Outcome and management in infants with esophageal atresia - A single centre observational study.

Donoso F, Kassa AM, Gustafson E, Meurling S, Lilja HE.

J Pediatr Surg. 2016 Sep;51(9):1421-5. doi: 10.1016/j.jpedsurg.2016.03.010. Epub 2016 Apr 5.

PMID:
27114309
47.

Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H.

Eur Urol. 2017 Jan;71(1):46-52. doi: 10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13.

48.

Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.

Krzyzanowska A, Lippolis G, Helczynski L, Anand A, Peltola M, Pettersson K, Lilja H, Bjartell A.

J Histochem Cytochem. 2016 May;64(5):311-22. doi: 10.1369/0022155416640466. Epub 2016 Mar 29.

49.

Author Reply.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 May;91:17-8. doi: 10.1016/j.urology.2015.12.069. Epub 2016 Mar 15. No abstract available.

PMID:
26992811
50.

Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.

Sjöblom L, Saramäki O, Annala M, Leinonen K, Nättinen J, Tolonen T, Wahlfors T, Nykter M, Bova GS, Schleutker J, Tammela TL, Lilja H, Visakorpi T.

PLoS One. 2016 Mar 3;11(3):e0150241. doi: 10.1371/journal.pone.0150241. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0153732.

Supplemental Content

Support Center